There is nothing specific about PAR management rather the market has marked down PR for creating repetitious milestone ambiguity.
When it comes to investing and in particular biotechs you have to embrace the process and most importantly be willingly to shoulder the inherent uncertainty and pain that comes with it.
- Forums
- ASX - By Stock
- PAR
- Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-387
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 11571 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 0.245 |
8 | 120363 | 0.240 |
5 | 126753 | 0.235 |
5 | 146782 | 0.230 |
2 | 53000 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 11571 | 1 |
0.260 | 15236 | 1 |
0.265 | 59987 | 2 |
0.270 | 10000 | 1 |
0.275 | 16347 | 3 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online